Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Loss per share - Schedule of Loss Per Share (Details)

v3.24.2.u1
Loss per share - Schedule of Loss Per Share (Details) - USD ($)
12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2022
Earnings per share [line items]      
Loss for the year attributable to Virax $ (6,733,537) $ (5,457,494) $ (1,708,827)
Basic loss per share attributable to Virax - ordinary shares $ (3.36) $ (5.13) $ (1.79)
Diluted loss per share attributable to Virax - ordinary shares $ (3.36) $ (5.13) $ (1.79)